VR Adviser as of March 31, 2022
Portfolio Holdings for VR Adviser
VR Adviser holds 27 positions in its portfolio as reported in the March 2022 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Aclaris Therapeutics (ACRS) | 12.7 | $79M | 4.6M | 17.24 | |
| Instil Bio | 12.0 | $74M | 6.9M | 10.75 | |
| Relmada Therapeutics (RLMD) | 9.9 | $61M | 2.3M | 26.99 | |
| Travere Therapeutics (TVTX) | 8.3 | $51M | 2.0M | 25.77 | |
| GH Research Ord Sh (GHRS) | 6.1 | $38M | 2.1M | 18.29 | |
| Tricida | 6.0 | $37M | 4.5M | 8.22 | |
| Miragen Therapeutics (VRDN) | 5.6 | $34M | 1.9M | 18.49 | |
| Marinus Pharmaceuticals (MRNS) | 4.8 | $30M | 3.2M | 9.35 | |
| Celldex Therapeutics (CLDX) | 4.8 | $30M | 865k | 34.06 | |
| Aadi Bioscience (AADI) | 4.2 | $26M | 1.5M | 16.97 | |
| Chinook Therapeutics | 3.4 | $21M | 1.3M | 16.36 | |
| LianBio Spons Adr (LIANY) | 3.2 | $20M | 5.4M | 3.71 | |
| Vistagen Therapeutics | 3.2 | $20M | 16M | 1.24 | |
| Athira Pharma (ATHA) | 2.2 | $14M | 1.0M | 13.50 | |
| Eiger Biopharmaceuticals | 2.0 | $12M | 1.5M | 8.30 | |
| Nuvalent Inc-a (NUVL) | 1.8 | $11M | 804k | 13.89 | |
| Graphite Bio | 1.3 | $8.2M | 1.6M | 5.10 | |
| Provention Bio | 1.3 | $8.2M | 1.1M | 7.32 | |
| Cogent Biosciences (COGT) | 1.3 | $8.2M | 1.1M | 7.49 | |
| Atyr Pharma (ATYR) | 1.2 | $7.5M | 1.4M | 5.35 | |
| Affimed Therapeutics B V | 1.0 | $6.2M | 1.4M | 4.37 | |
| Sierra Oncology | 0.8 | $5.2M | 163k | 32.05 | |
| Altimmune (ALT) | 0.7 | $4.6M | 760k | 6.09 | |
| Centessa Pharmaceuticals Spons Adr (CNTA) | 0.6 | $3.7M | 411k | 8.97 | |
| Astria Therapeutics (ATXS) | 0.6 | $3.6M | 539k | 6.71 | |
| Aerovate Therapeutics (AVTE) | 0.4 | $2.8M | 151k | 18.33 | |
| Savara (SVRA) | 0.4 | $2.5M | 1.9M | 1.31 |
